Mostrar el registro sencillo del ítem

dc.contributor.authorMorente López, Miriam*
dc.contributor.authorMato Basalo, Rocío*
dc.contributor.authorLucio-Gallego, S.*
dc.contributor.authorGil, C.*
dc.contributor.authorCarrera, M.*
dc.contributor.authorFafian Labora, Juan*
dc.contributor.authorMateos Martín, Jesús *
dc.contributor.authorArufe Gonda, Mª del Carmen*
dc.date.accessioned2025-09-09T10:23:28Z
dc.date.available2025-09-09T10:23:28Z
dc.date.issued2023
dc.identifier.citationMorente-López M, Mato-Basalo R, Lucio-Gallego S, Gil C, Carrera M, Fafián-Labora JA, et al. Effect of miR-21 in mesenchymal stem cells-derived extracellular vesicles behavior. Stem Cell Research and Therapy. 2023;14(1).
dc.identifier.issn1757-6512
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/65911de9ae63c86e421ba13a
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21393
dc.description.abstractBackground: A challenging new branch of research related to aging-associated diseases is the identification of miRNAs capable of modulating the senescence-associated secretory phenotype (SASP) which characterizes senescent cells and contributes to driving inflammation. Methods: Mesenchymal stem cells (MSC) from human umbilical cord stroma were stable modified using lentivirus transduction to inhibit miR-21-5p and shotgun proteomic analysis was performed in the MSC-derived extracellular vesicles (EV) to check the effect of miR-21 inhibition in their protein cargo. Besides, we studied the paracrine effect of those modified extracellular vesicles and also their effect on SASP. Results: Syndecan-1 (SDC1) was the most decreased protein in MSC-miR21?-derived EV, and it was involved in inflammation and EV production. MSC-miR21?-derived EV were found to produce a statistically significant inhibitory effect on SASP and inflammaging markers expression in receptor cells, and in the opposite way, these receptor cells increased their SASP and inflammaging expression statistically significantly when treated with MSC-miR-21+-derived EV. Conclusion: This work demonstrates the importance of miR-21 in inflammaging and its role in SASP through SDC1. Graphical abstract: [Figure not available: see fulltext.]
dc.description.sponsorshipJ.A.F-L was funded by Xunta de Galicia, Grants Number (ED481D-2021-020, 11_IN858A_2021_114114 and ED431F 2023/030), the Ministerio de Ciencia e Innovacion (RYC2021-032567-I) and the InTalent program from UDC-Inditex for the research grant. J.M. acknowledge the support of Xunta de Galicia (GAIN) by Talent Senior research grant (11_IN858A_2021_1141142). M.C.A. has been funded by Instituto de Salud Carlos III through the project PI20/00497. Co-funded by European Regional Development Fund A way to make Europe. Subsidy granted by the Carlos III Proteomics Network Platform, ProteoRed, within the ProteoRed Proof of Concept Projects program. The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
dc.languageeng
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshHumans *
dc.subject.meshProteomics *
dc.subject.meshMicroRNAs *
dc.subject.meshInflammation *
dc.subject.meshExtracellular Vesicles *
dc.subject.meshMesenchymal Stem Cells*
dc.titleEffect of miR-21 in mesenchymal stem cells-derived extracellular vesicles behavior
dc.typeArtigo
dc.authorsophosMorente-López, M.; Mato-Basalo, R.; Lucio-Gallego, S.; Gil, C.; Carrera, M.; Fafián-Labora, J.A.; Mateos, J.; Arufe, M.C.
dc.identifier.doi10.1186/s13287-023-03613-z
dc.identifier.sophos65911de9ae63c86e421ba13a
dc.issue.number1
dc.journal.titleStem Cell Research and Therapy*
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Biomédica de A Coruña (INIBIC)
dc.organizationInstituto de Investigación Biomédica de A Coruña (INIBIC)
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario A Coruña::Unidade de investigación
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Lugo::Oncoloxía médica
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Biomédica de A Coruña (INIBIC)::Fisioterapia
dc.relation.projectIDXunta de Galicia [ED481D-2021-020, 11_IN858A_2021_114114, ED431F 2023/030]
dc.relation.projectIDMinisterio de Ciencia e Innovacion [RYC2021-032567-I]
dc.relation.projectIDInTalent program from UDC-Inditex
dc.relation.projectIDXunta de Galicia (GAIN) by Talent Senior research grant [11_IN858A_2021_1141142]
dc.relation.projectIDInstituto de Salud Carlos III [PI20/00497]
dc.relation.projectIDEuropean Regional Development Fund A way to make Europe
dc.relation.projectIDCarlos III Proteomics Network Platform, ProteoRed, within the ProteoRed Proof of Concept Projects program
dc.relation.publisherversionhttps://doi.org/10.1186/s13287-023-03613-z
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS A Coruña
dc.subject.keywordINIBIC
dc.subject.keywordINIBIC
dc.subject.keywordAS A Coruña
dc.subject.keywordCHUAC
dc.subject.keywordAS Lugo
dc.subject.keywordCHULA
dc.subject.keywordAS A Coruña
dc.subject.keywordINIBIC
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number14


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 International (CC BY 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International (CC BY 4.0)